Hydroxyamphetamine

Summary

Hydroxyamphetamine (CHEMBL1546) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 151.21 Da · C9H13NO

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1546
Name	Hydroxyamphetamine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	3651
Molecular formula	C9H13NO
Molecular weight	151.21
InChIKey	GIKNHHRFLCDOEU-UHFFFAOYSA-N

SMILES: CC(CC1=CC=C(C=C1)O)N

IUPAC name: 4-(2-aminopropyl)phenol

Also known as: Dl-p-hydroxyamphetamine, Hidroxianfetamina, Hydroxyamfetamine, Norveritol, NSC-170995, P-hydroxyamphetamine, Pulsoton, Racemic p-hydroxyamphetamine, (rac)-p-Hydroxyamphetamine, alpha-Methyltyramine, hydroxyamphetamine, HYDROXYAMFETAMINE

Parent form; salt/anhydrous children: CHEMBL1200705

Patent coverage: 915 distinct patent families (3,221 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Sodium-dependent noradrenaline transporter, Trace amine-associated receptor 1.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 3 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
Q923Y9	7.3	EC50	50	nM	CHEMBL_ACT_7968705
Q923Y9	7.29	EC50	51	nM	CHEMBL_ACT_18042030
SLC6A2	5.01	AC50	9660	nM	CHEMBL_ACT_25146460

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).